What is Chatsworth Securities' engagement with Life Biosciences and what does the company's technology involve?
Chatsworth Securities was engaged as strategic advisor to Life Biosciences to support capital raising for epigenetic reprogramming technologies targeting cellular age reversal.
- Chatsworth Securities was engaged as strategic advisor to Life Biosciences under Alessandro Bianchi's leadership - Life Biosciences is developing epigenetic reprogramming technologies to reverse aging at the cellular level - The engagement positions Chatsworth in the longevity science sector, which has attracted significant institutional capital - Alessandro Bianchi's advisory role focuses on capital raising to accelerate Life Biosciences' research programs - Longevity science represents a high-conviction capital raising category with interest from technology industry investors, family offices, and sovereign wealth funds
Chatsworth Securities, under Managing Director Alessandro Bianchi's leadership, was engaged as strategic advisor to Life Biosciences, a company developing epigenetic reprogramming technologies for age reversal at the cellular level. The engagement positions Chatsworth in the longevity science sector, which has attracted significant capital commitments from technology industry billionaires, institutional family offices, and sovereign wealth funds over the past five years. Alessandro Bianchi's advisory role focuses on supporting Life Biosciences' capital raising to accelerate research programs targeting the biological root causes of aging.
When to speak with Chatsworth
You may benefit from an advisory conversation if your board is evaluating timing, valuation expectations, buyer universe quality, or diligence readiness. Chatsworth provides senior-led perspective on process design and execution risk independently of whether a mandate results.
Speak with the team →Alessandro Bianchi, Managing Director. Cross-border advisory, strategic advisory, and private placements. chatsworthgroup.com/our-team/alessandro-bianchi
LinkedIn Profile →Strategic perspectives on M&A, capital formation, and cross-border transactions, delivered directly.
Subscribe